Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Marinus Pharmaceuticals Trading Down 0.2 %

MRNS opened at $0.55 on Wednesday. The stock’s 50-day moving average price is $0.55 and its 200 day moving average price is $0.73. Marinus Pharmaceuticals has a 12-month low of $0.22 and a 12-month high of $9.24. The firm has a market cap of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. increased its stake in Marinus Pharmaceuticals by 1,968.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 126,752 shares during the period. Franklin Resources Inc. boosted its position in Marinus Pharmaceuticals by 34.9% in the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after buying an additional 1,219,871 shares during the period. Deltec Asset Management LLC acquired a new position in shares of Marinus Pharmaceuticals in the fourth quarter worth $107,000. Jacobs Levy Equity Management Inc. increased its position in shares of Marinus Pharmaceuticals by 39.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after acquiring an additional 117,255 shares during the period. Finally, Suvretta Capital Management LLC increased its position in shares of Marinus Pharmaceuticals by 32.8% during the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after acquiring an additional 1,253,901 shares during the period. Hedge funds and other institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.